

RPS Science and Research Summit 2019

Speaker Biographies

Dr Diane Ashiru-Oredope, Pharmacist Lead for Antimicrobial Resistance and Stewardship, Public Health England



Dr Diane Ashiru-Oredope is the Lead Pharmacist for HCAI & AMR division, National Infection Service, Public Health England (PHE) and the Department of Health Expert Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI). An antimicrobial pharmacist by background, she chaired the multi-professional subgroup that updated the national antimicrobial stewardship toolkit for secondary care, Start Smart - then Focus, and project-led the ARHAI/PHE national Antimicrobial Prescribing and Stewardship Competences.

She is a committee member for the UK Clinical Pharmacy Association Pharmacy Infection Network, member of the Royal Pharmaceutical Society AMR Expert Advisory Group and Commonwealth Pharmacists Association's Global AMR Lead. Her research interests include Antimicrobial Stewardship, monitoring antimicrobial consumption and behaviour change/insights interventions to tackle antimicrobial resistance.

Dr Andy Blackwell, Chief Scientific Officer, Ieso Digital Health



Andy specialises in the development and application of digital technology to understand, prevent, diagnose, monitor and treat conditions affecting mental health.

Following doctoral research, Andy worked as a medical research scientist in world-leading psychology and neuroscience laboratories at the University of Cambridge. He then became Chief Scientific Officer of Cambridge Cognition, a fast-growth mental health and neuroscience technology business which went on to successful public listing on the AIM market. In 2015 Andy joined Ieso Digital Health as CSO where his key role is to lead product strategy, clinical data science and advanced technologies research

programmes.

Ieso Digital Health is an award-winning provider of evidence-based mental health therapy online, operating in the UK and USA. Leveraging breakthrough technology and clinical data science, Ieso offers improved outcomes, lower costs and on-demand access to world class mental healthcare at any time or location convenient to patients.

Matt Bonam, Director, Intelligent Pharmaceuticals, AstraZeneca



Matt Bonam is the Global Head of AZ's Intelligent Pharmaceuticals group and has published and presented extensively on the impact digital health solutions can have on healthcare delivery and the pharmaceutical industry. Matt founded the Intelligent Pharmaceuticals group within AZ in 2013 to design, develop, evaluate and implement digital therapeutic devices to improve clinical outcomes for patients in AZ's core therapy areas. Since 2013 the group has delivered a number of successful digital therapeutics using connected drug delivery devices, medical sensors, behavioural interventions and medical device software.

Professor Christine Bond, (BPharm (Hons.), Med, PhD, FRPharmS, FFRPS FFPH FRCPE, FRCGP), University of Aberdeen



Christine is Emeritus Professor and past Head of Centre of Academic Primary Care. She is Editor of the International Journal of Pharmacy Practice and Chair of the Royal Pharmaceutical Society Science and Research Board.

From 1996-2012, Christine was part-time Consultant in Pharmaceutical Public Health (NHS Grampian) in which role she was developing new community pharmacy and general practice-based services.

She has been awarded well over 100 research grants and has over 250 publications relating to her research on the contribution of pharmacy to the delivery of healthcare, and has a particular interest in the pharmacist's role in the evidence-based cost-effective use of medicines. In 2010 she was awarded the Pharmas Lifetime

Achievement Award. She has previously been an elected member of the Scottish Pharmacy Board.

Professor Chas Bountra, Pro-Vice Chancellor for Innovation, University of Oxford



Chas has 30 years of experience of novel target discovery in academia and industry, and in the identification of new molecules for clinical POC and full development. He has progressed more than 20 molecules into Phase II studies.

Chas's group (130 scientists) are world leaders in membrane protein and kinase structural biology, epigenetics chemical biology and 'open' target discovery. He is now focused on generating novel early discovery tools for novel high priority genes. He has been voted one of the top innovators in the industry and has received an award from the Royal Society of Chemistry.

Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence



Andrew Dillon graduated from the University of Manchester in 1975. He has held a number of senior management positions in the UK National Health Service, including General Manager of the Royal Free Hospital and Chief Executive of St George's Healthcare NHS Trust in London.

He joined NICE as its founding Chief Executive in 1999.

Professor Chris Dowson, Professor of Microbiology, University of Warwick



Professor Chris G Dowson has, for many years, examined the emergence and evolution of antibiotic resistance across a wide range of bacteria. His recent focus has been to better understand how penicillin targets bacteria. This began during his postdoctoral time at the University of Sussex, in the laboratory of Professor Spratt (1986-1990) and subsequently with his Lister Institute Centenary Fellowship (1991-1996). He currently holds a personal chair at Warwick University and is a member of the Medical Research Council Infections and Immunity Board.

Chris' research is funded by BBSRC, MRC, Wellcome Trust and industry. It is highly collaborative, involving teams of biologists, chemists, engineers and physicists across universities in the UK ([SWON Alliance](#)), CA, CHN ([Accelerate CHNUK](#)), US, SA, EU, AUS

to help drive innovations from this research forward to a commercial outcome. The development of new reagents and new assays are crucial underpinning technologies enabling a multi-target focus to antibiotic discovery, with

priorities in peptidoglycan biosynthesis (multi-targeting penicillin binding proteins and Mur ligases) and protein biosynthesis (multi-targeting tRNA synthetases).

Emma Foreman, Consultant Pharmacist, Royal Marsden NHS Foundation Trust, London, UK



Emma has been a hospital pharmacist for over 20 years, working in a variety of different hospitals from small district generals to large teaching hospitals – including a tiny mission hospital in Ghana! She specialised in oncology in 2001, taking on both technical and clinical roles, qualifying as an independent prescriber in 2010 and completing an MSc in clinical oncology at Birmingham University in 2011. She is a visiting lecturer at University of Brighton and has helped to develop a case-based lecture series around a breast cancer case.

As Consultant Pharmacist, Emma works with a multidisciplinary team to innovate and implement chemotherapy service improvements as well as working with the pharmacy team to promote the role of pharmacists as advanced practitioners and develop a pharmacist-led research portfolio. She is currently on the executive committee of the British Oncology Pharmacy Association (BOPA) and Chairs a Biosimilars Taskforce for the International Society for Oncology Pharmacy Practitioners (ISOPP).

Dr Amira Guirguis, Lecturer in Pharmaceutical Science, University of Hertfordshire



Amira originally trained as an accountant before gaining an interest in pharmacy, which resulted in the completion of an MPharm degree from the University of Hertfordshire and multiple awards including the JOEL medal and the General Pharmaceutical Council, mental health and pharmaceutical chemistry research awards. Amira gained her PhD in the in-field detection of New Psychoactive Substance (NPS), which cumulated in the publication of several papers and the JPAG's Geoffrey Phillips award. Amira joined the University of Hertfordshire as a lecturer in Pharmaceutical Chemistry and has contributed to the chemical analysis work stream of two high-profile EU Commission funded grants: EU-MADNESS (EU-wide monitoring, analysis and knowledge dissemination on NPS) and EPS/NPS

(enhancing police skills on NPS).

Amira has also contributed to the RPS NPS quick reference guide and fact sheet for pharmacists, and the NPS monographs in Clarke's Analysis of Drugs and Poisons to assist with the identification of NPS by front-line workers.

Jatinder Harchowal, Chief Pharmacist, The Royal Marsden Hospital, London



Jatinder has been a hospital pharmacist for over 25 years. He is currently Chief Pharmacist and a Clinical Director in the Royal Marsden Hospital (RMH), a world leading cancer hospital, leading a team of 140 staff to ensure patients receive the most up-to-date medicines in the safest way. Jatinder is also the medicines lead for the RM Partners West London Cancer Alliance - a programme designed to test new and innovative pathways to improve the earlier diagnosis of patients with cancer - and recently led on a programme to introduce biosimilar Rituximab safely and consistently in oncology. Jatinder is currently the Chair of the Royal Pharmaceutical Society's Hospital Expert Advisory Group and the London Chief Pharmacists Group.

Jatinder has been a Chief Pharmacist for over 14 years in various hospitals including Brighton and Ealing. Jatinder has previously worked in a number of different pharmacist roles in various hospitals across London, including Barts, King's College and Charing Cross Hospitals.

Professor Alison Holmes, Director, Health Protection Research Unit, National Institute for Health Research



Alison Holmes is a Professor of Infectious Diseases at Imperial College, a Fellow of the Academy of Medical Sciences and an NIHR Senior Investigator. She has a longstanding clinical and research career in infectious diseases with particular interests in antibiotic use, antibiotic resistance (AMR), epidemiology and public health, particularly in the context of acute care. She leads a large multi-disciplinary research group and network, with strong collaborations nationally and internationally, and is Director of the National Institute of Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and AMR. She is on the Executive Committee of the International Society of Infectious Diseases, and serves on a variety of WHO Expert groups related to antimicrobial use, AMR, infection prevention and sepsis. She is Chair of the Fleming Fund's Technical Advisory Group (Department of Health and Social Care) and Board Member of the Wellcome Trust's Surveillance & Epidemiology of Drug-resistant Infections Consortium (SEDRIC). She chairs or sits on numerous international scientific advisory boards, funding panels and editorial boards.

Philip Howard, President, British Society for Antimicrobial Chemotherapy



Philip Howard is Consultant Pharmacist in Antimicrobials at the Leeds Teaching Hospitals NHS Trust, a National AMR Project Lead at NHS-Improvement and Visiting Professor at Leeds University.

He is the President of the British Society of Antimicrobial Chemotherapy (a global antibiotic charity), and a spokesman for the Royal Pharmaceutical Society and International Pharmaceutical Federation on Antimicrobials and Antimicrobial Resistance.

Philip was a member of the Department of Health ARHAI Antimicrobial Stewardship Group which produced the original Start Smart then Focus Antimicrobial Stewardship Guidelines, and the HPA Primary Care Unit which helped to produce the RCGP TARGET guidance on Antimicrobial Stewardship in Primary Care.

Philip's research interests are in Antimicrobial Stewardship and improving antibiotic use. He led the first global hospital Antimicrobial Stewardship survey and has been involved in AMS education and training across the world. Philip has been made a fellow of the Royal Pharmaceutical Society, and has won the GHP/GSK/UKCPA Clinical Leadership Award and the UKCPA Lifetime Achievement Award.

Mike Isles, Executive Director, The Alliance of Safe Online Pharmacies EU (ASOP EU)



Mike is the Executive Director of the Alliance for Safe Online Pharmacy in the EU ([ASOP EU](#)). There are an estimated 130 million European citizens buying medicines online. And with over 35,000 pharmacy websites operating illegally, this multisectoral organisation's mission is to enable patients to buy their medicines online safely – where it is legal to do so. With over 50 participants involving many key Internet stakeholders, its aim is to raise public awareness and to produce concrete voluntary actions that will make a real difference and ultimately benefit the health of patients.

Mike is also Executive Director of the European Alliance for Access to Safe Medicines ([EAASM](#)). The EAASM is a pan-European patient safety organisation, bringing together all concerned with eliminating falsified medicines from the supply chain. The EAASM also champions patient safety issues relating to medical practices that can severely compromise patients' welfare and rights.

Mike is also European Medicines Partnership Director for [International Health Partners](#), a UK charity whose Queen's Award for Enterprise for continuous Innovation in 2011 recognises the tremendous humanitarian work sourcing donated quality medicines from the pharmaceutical industry and coordinating delivery via secure supply chain solutions to disaster-struck areas in close liaison with NGOs.

Professor Trevor M Jones CBE. FMedSci.



Professor Jones is Chairman of the international Clinical Research Organisation, Simbec-Orion (HQ in Merthyr Tydfil) and Board member of the Global Life Sciences investment company; Aris Bioscience plc; the Oxford based Drug Discovery Company, e-Therapeutics plc; and the UK Stem Cell Foundation (UKSCF). He was a Director of Allergan Inc (USA) and formerly R&D Director of The Wellcome Foundation where he was responsible for the development of AZT (HIV/AIDS), Zovirax (Herpes), Lamictal (Epilepsy), Malarone (Malaria) and other medicines. Also Director General of The Association of the British Pharmaceutical Industry (ABPI), he is a member of the Wales Government, Bevan Commission and the Advisory Board of the Universities of Swansea and Surrey.

Prof Jones is a visiting professor and former Vice-Chairman of Council at King's College, London; holds honorary degrees and Gold Medals from 6 universities; is a founder member of the Geneva-based, Public: Private Partnership, Medicines for Malaria Venture (MMV), and has continued to be involved in the Development of anti-malarial medicines: most recently Eurartesim.

Dr Jane Marshall MRCPI FRCPsych, Consultant Psychiatrist, Mental Health and Addiction Services, South London and Maudsley NHS Foundation Trust



Jane is a consultant psychiatrist in addiction at the South London and Maudsley NHS Foundation Trust (SLaM) and visiting senior lecturer at the Institute of Psychiatry, Psychology and Neuroscience, Kings College London. She works in complex care addiction services and has a special interest in addicted healthcare professionals.

She is based at SLaM and at the NHS Practitioner Health Programme (PHP), a dedicated service for doctors and dentists with mental health and addiction problems. She is a consultant advisor in psychiatry (Drugs and Alcohol) to the Civil Aviation Authority (CAA); a health examiner and medical supervisor for the General Medical Council and a medical member of the DVLA Medical Advisory Panel for alcohol, drugs, substance misuse and driving. She does partnership work with local GPs in a South London voluntary sector detoxification unit.

Professor Gino Martini, Chief Scientist, Royal Pharmaceutical Society



Professor Martini is Chief Scientific Officer for the Royal Pharmaceutical Society and Chief Scientist for Bioepic Ltd, a Med-Tech company specialising in non-invasive blood sugar monitoring (<https://epichealth.io/>).

Professor Martini is a registered practicing industrial pharmacist and a Fellow of the Royal Pharmaceutical Society. Professor Martini also divides his time between the Pharmaceutical Industry and King's College London as a visiting professor in Pharmaceutical Innovation, after having held the Chair in Pharmaceutical Innovation at King's for 5 years. Prior to this, Professor Martini spent over 17 years working at GlaxoSmithKline Pharmaceuticals, Roche Products Ltd. and Shire Pharmaceuticals working in a variety of commercial, innovative technology based and medical affairs roles; directing groups in the US, Europe and emerging markets. He has an MBA specializing in SME success and business failure awarded with distinction from the University of Liverpool.

Professor Anthony C. Moffat BPharm, PhD, DSc, FRPharmS



Professor Moffat is Emeritus Professor of Pharmaceutical Analysis at the UCL School of Pharmacy. He was previously Professor of Pharmaceutical Analysis and Head of the Centre for Pharmaceutical Analysis, which provided a focus for research and education in pharmaceutical analysis within the school and extended the world-class knowledge base in that field. In particular, near-infrared spectroscopy was being used: to further the technique, increase its use in the pharmaceutical industry and get it accepted by the regulatory authorities.

He was previously Chief Scientist at the Royal Pharmaceutical Society of Great Britain where he gave advice on scientific matters to the Society's Council and other departments within the Society. Part of his duties was to write policy papers concerning the scientific aspects of pharmaceutical healthcare and how it may be delivered to the community at large. He has extensive first-hand knowledge of pharmacy in the community, academic and hospital settings, and has excellent links to the pharmaceutical industry. He also acted as the Society's scientific spokesperson for the media.

He has over 370 publications as well as co-authorship of 7 books (including Clarke's Analysis of Drugs and Poisons).

Dr Bernard D. Naughton PhD., MPharm. (Hons), Dip. Clin. Pharm., MRPharmS



Dr Bernard Naughton is a postdoctoral researcher at the Saïd Business School, the University of Oxford, working within the TOPOS research group. Bernard is also a clinical pharmacist at Oxford University Hospitals NHS Foundation Trust (OUHFT).

Bernard's research relates to falsified medicines, the pharmaceutical supply chain, associated international policy, and responsible research and innovation in digital health and welfare services. Bernard is a clinical pharmacist by background and has implemented an FMD mandated medicines screening technology at OUHFT as part of a research project from 2015 to 2018. This research involved the integration and testing of a drug screening technology within PMR software. Bernard is now working on a pilot which involves the evaluation of a stand-alone FMD drug screening technology at OUHFT. Bernard's other research relates to the commercialisation of digital health technology and the impact of responsible innovation on commercialisation in the current landscape.

Cath O'Brien, Director, Welsh Blood service



Cath joined Welsh Blood Service, Velindre University NHS Trust as Director in 2013.

She is currently the Co-Director of the Midland Wales Advanced Therapy Treatment Centre, a new initiative funded by Innovate UK to identify barriers and challenges and facilitate future deployment and adoption of ATMPs within the UK and is also supporting the Welsh Government Chief Medical officer in the development of a Statement of Intent for Advanced Therapies. She is also a member of the Life Sciences Hub Wales Board.

A Pharmacist by profession, Cath spent her early career in retail pharmacy in Cardiff and the South Wales Valleys before moving to senior roles with Cooperative Pharmacy. In 2002 she joined the Royal Pharmaceutical Society as Director for Wales and Interim Director of Corporate Affairs where she played a key role in the establishment of the RPS as the new professional body.

Professor Mahendra G Patel, BPharm PhD FRPharmS, Alumni Fellow NICE FHEA



Mahendra is a highly respected pharmacist and senior academic fellow with a national and international profile. He is an elected board member and Treasurer for the Royal Pharmaceutical Society. His other roles include Honorary Senior Lecturer at the Medical School of The University of Sheffield and Adjunct Professor of Pharmacy, Wilkes University, Pennsylvania, USA. He was one of the first to be recognised as a Fellow of the National Institute of Health and Care Excellence (NICE) during 2010-2013, and for many years has been an advisory member of various panels and committees of NICE.

Mahendra's career spans community pharmacy, health education and health promotion, academia and research. He has helped lead the way forward for the pharmacy profession UK-wide for many years. This has culminated in him receiving the Royal Pharmaceutical Society's prestigious President's Charter Award 2016 for his exceptional services in advancing the profession and promoting the interests of pharmacy locally, nationally, and internationally.

Jo Pisani, Partner, Pharmaceuticals and Lifesciences Strategy, PwC



Jo Pisani is a Partner leading the UK Pharma and Lifesciences Consulting Practice. She has thirteen years of industry experience in the pharmaceuticals, energy, petrochemicals, and fast-moving consumer goods industries with BP and SmithKline Beecham where she held positions in the engineering, operations, IT, and commercial functions. Before joining PwC she spent three years with Booz&Co, a strategic management consultancy where she focused on strategic issues in the pharmaceuticals and energy sectors.

Jo assists the pharma and lifesciences sector in developing strategy and supporting deals. Her clients include Big Pharma, biotech, generics, OTC, contract manufacturers, contract research organisations, ministries of health, private equity and banks. She is a key author on PwC's Pharma2020 thought leadership series and is also an advisory board member of MedCity.

Jo has an MBA from Warwick Business School and is a Chartered Engineer.

Professor Sir Michael Rawlins MD FRCP FMedSci



Sir Michael is Chairman of the Medicines and Healthcare products Regulatory Agency since December 2014. He is a clinical pharmacologist and specialist in internal medicine. He was professor of clinical pharmacology in Newcastle, and physician at the Newcastle Hospitals from 1999-2006.

Sir Michael was Chairman of the Committee on Safety of Medicines (1992-1998), Chairman of the Advisory Council on the Misuse of Drugs (1998-2008) and founding Chairman of the National Institute for Clinical Excellence (1999-2013). He is recent past-president of the Royal Society of Medicine (2012-2014).

Currently Sir Michael is Chairman of UK Biobank, honorary professor at the London School of Hygiene and Tropical Medicine, and emeritus professor at the University of Newcastle upon Tyne.

Sir Michael was appointed Chairman of the Medicines and Healthcare products Regulatory Agency (MHRA), on the 1st December 2014.

Professor David Taylor, BSc MSc PhD FCMHP FFRPS FRPharmS



Professor David Taylor is Director of Pharmacy and Pathology at the Maudsley Hospital and Professor of Psychopharmacology at King's College. In 2014, Professor Taylor was ranked in the top 100 clinical leaders in the NHS by the Health Service Journal.

Professor Taylor is the Editor-in-Chief of the journal, *Therapeutic Advances in Psychopharmacology*. He is also Head of Pharmaceutical Sciences Clinical Academic Group in King's Health Partners and has served as the pharmacological expert on five NICE Guideline panels since 2002.

Professor Taylor has been the lead author of the Maudsley Prescribing Guidelines since their inception in 1993. The Maudsley Prescribing Guidelines have sold over 300,000 copies in thirteen editions and twelve languages. Professor Taylor has also authored over 275 clinical papers in journals such as the BMJ, British Journal of Psychiatry and Journal of Clinical Psychiatry. These papers have been cited over 10,000 times. Professor Taylor has an H Index of 57.

Dr Claire Thompson, CEO, Agility Health Tech



Claire is an award-winning scientist and innovator with more than 15 years' experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual and Contract Research Organisations.

Claire is also the founder of Agility Health Tech, a consulting and communications firm which works with organisations across the healthcare space to advance their products and raise their profile.

She was honoured with the Royal Pharmaceutical Society's Pharmaceutical Science Award in 2015, and the Academy of Pharmaceutical Sciences' Medal in 2016. Before founding Agility Health Tech, she was Head of Research and Development with Oxford PharmaScience, an AIM-listed virtual pharmaceutical company identified as one of the "Top 10 Emerging Technology Companies 2012". Prior to this, Claire was Associate Director at Juniper Pharmaceuticals and spent 7½ years at GlaxoSmithKline and Pfizer developing novel molecules and formulations for therapeutic areas such as asthma, cancer, HIV, insomnia, malaria and pain. Claire was Chief Scientist of the Academy of Pharmaceutical Sciences from 2012-2016.

Professor Neil Watson, Clinical Director of Pharmacy and Medicines Optimisation, Newcastle upon Tyne Hospitals NHS Foundation Trust



Neil is the Clinical Director of Pharmacy and Medicines Optimisation at The Newcastle upon Tyne Hospitals NHS Foundation Trust, leading a team of 300 staff working across two sites, The Royal Victoria Infirmary and The Freeman Hospital, a post which he has held since April 2007.

Neil's primary areas of interest are Advanced Therapies and Integrated Care, particularly ensuring a co-ordinated approach to medicines optimisation across healthcare sectors and Clinical Informatics, supporting data driven care.

Cheryl Way, Pharmacy and Medicines Management Lead, NHS Wales Informatics Service



Cheryl graduated from Cardiff University with an honours degree in pharmacy. She completed pre-registration training in the pharmaceutical industry and hospitals in Surrey. She joined the NHS as a medicines information pharmacist in the Welsh Medicines Information Centre, then worked as a hospital pharmacist at Cardiff Royal Infirmary before becoming Pharmacy Manager for Cardiff Royal Group of Hospitals. She obtained a Master's degree in Healthcare Management from the University of Glamorgan in 1996 and worked at the University Hospital of Wales before becoming Pharmacy Manager at University Hospital Llandough in 2001.

Cheryl joined Informing Healthcare, now NHS Wales Informatics Service, as National Pharmacy and Medicines Management Lead in 2006 before completing the Leaders for Change Programme with The Health Foundation in 2009 and receiving the Leaders for Collaboration certificate from Cardiff Metropolitan University in 2014. She was elected to the Welsh Board of the Royal Pharmaceutical Society in 2015, and awarded fellowship of the Society in 2017.

Professor Kim Wolff MBE, Professor of Analytical, Forensic & Addiction Science, King's College London



Professor Wolff has been involved in the addictions field for over 20 years. Her main research interest is concerned with biomarkers of substance misuse and she has acted as an expert advisor to several international bodies including the European Transport Safety Council (ETSC), contributing to a report that was presented to the **European Parliament on drug-driving**; the ACT Safety Forum on Drug-Driving legislation (Australasian College of Road Safety) and; the 'Foundation for the Wellbeing of Society' organised by Her Excellency the President of Malta (2015) on drug-driving legislation.

Professor Wolff was funded by the Department for Transport to investigate biomarkers for alcohol misuse in drivers and her work has led to advancement in the area of biomarkers for High Risk Drink-Drivers. In 2016 Professor Wolff received an MBE in the New Year's Honours for her work on introducing new drug-driving legislation. She has chaired a second panel on behalf of the Department for Transport to make recommendations concerning alternative matrices for evidential testing in those apprehended for drug-driving offences. Most recently, she has acted as an expert advisor for the WHO Expert Committee for Drug Dependence (ECDD) for reviews of cannabis and tramadol.